EX-12.2 4 a2237040zex-12_2.htm EX-12.2
QuickLinks -- Click here to rapidly navigate through this document


Exhibit 12.2

Agile Therapeutics, Inc.
Computation of Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends
For the Years Ended December 31, 2017, 2016, 2015, 2014, and 2013
(Dollars in thousands)

 
   Year Ended December 31,  
 
   2017   2016   2015   2014   2013  

Earnings:

                                

Pretax loss from continuing operations

   $ (28,304 )   (31,816 ) $ (36,307 ) $ (19,730 ) $ (14,321 )

Add:

                                

Fixed charges

     1,918     2,446     2,077     1,566     1,513  
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total Earnings

   $ (26,386 ) $ (29,370 ) $ (34,230 ) $ (18,164 ) $ (12,808 )
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Fixed Charges:

                                

Interest expensed, including amortized discounts and premiums

   $ 1,918   $ 2,446   $ 2,077   $ 1,566   $ 1,513  

Estimate of interest expense within rental expense

     —     —     —     —     —  

Preferred Stock Dividends

     —     —     —     —     —  
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total Fixed Charges

   $ 1,918   $ 2,446   $ 2,077   $ 1,566   $ 1,513  
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Ratio of Earnings to Fixed Charges

     n/a     n/a     n/a     n/a     n/a  
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Deficiency of Earnings Available to Cover Fixed Charges

   $ (28,304 ) $ (31,816 ) $ $(36,307 ) $ (19,730 ) $ (14,321 )
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​



QuickLinks

Agile Therapeutics, Inc. Computation of Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends For the Years Ended December 31, 2017, 2016, 2015, 2014, and 2013 (Dollars in thousands)